Previous 10 | Next 10 |
Pulmonary Disease Expert, Dr. Susan Garwood, is Hosted by CHEST to Discuss Standardized Risk Assessment to Enhance Referral Patterns for Patients with Lung Nodules Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung dise...
Findings to be Presented at AACR Annual Meeting Further Demonstrate the Utility of Protein Biomarker Data to Support Physicians in Patient Management Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today ann...
Diagnostic Test and Novel Methodologies Designed to Guide Patient Assessment and Treatment Strategies Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced that the United States Patent and Tradema...
The challenge by the U.S. Federal Trade Commission to block the proposed acquisition of Grail by Illumina ([[ILMN]] +4.0%) led to a ~6.6% sell-off of the stock yesterday.Citing a brighter post-COVID future for the company, Canaccord Genuity has upgraded the stock to buy from hold with the pri...
Increases Company’s Net Liquidity Position and Reduces Near-Term Cash Interest Costs Biodesix, Inc. (NASDAQ: BDSX; “Biodesix” or the “Company”) a leading data-driven diagnostic solutions company with a focus in lung disease, announced today...
Image source: The Motley Fool. Biodesix, Inc. (NASDAQ: BDSX) Q4 2020 Earnings Call Mar 16, 2021 , 4:30 p.m. ET Operator Continue reading For further details see: Biodesix, Inc. (BDSX) Q4 2020 Earnings Call Transcript
Biodesix (BDSX): Q4 GAAP EPS of -$0.25 beats by $0.09.Revenue of $27.03M (+226.8% Y/Y) beats by $11.56M.Press Release For further details see: Biodesix EPS beats by $0.09, beats on revenue
Full Year 2020 Revenue Growth of 86% on Record Revenue of approximately $46 million Biodesix, Inc. (NASDAQ: BDSX) a leading data-driven diagnostic solutions company with a focus in lung disease, today announced financial and operating results for the fourth quarter and full ...
Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced that it will release financial results for the fourth quarter and year ended December 31, 2020 after the close of trading on Tuesday, March 16. Biodesix...
Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced that The Healthcare Technology Report announced Chief Executive Officer, Scott Hutton, as one of the Top 25 Biotech CEOs of 2021 . This press relea...
News, Short Squeeze, Breakout and More Instantly...
Awarding Excellence in Company Culture Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company, is honored to announce it has been named to Inc. Magazine’s Best Workplaces list . The ranking is a result of a comprehensive, data-driven measurement pro...
Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company with a focus in lung disease, today announced Scott Hutton, Chief Executive Officer, will participate in two upcoming investor conferences: William Blair 44 th Annual Growth Stock Conference Presentation and 1x1...
Data highlights ability of the Nodify XL2 test to identify benign nodules in patients with emphysema Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company with a focus in lung disease, announced that new data will be presented today at the 2024 American Thoracic Society ...